# OnCo record contact-03 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/contact-03/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "contact-03", "NCT04338269" ;
  schema:name "CONTACT-03"@en ;
  schema:description "Continuing immunotherapy after it has failed, alongside a targeted pill, added nothing but side effects. The first definitive test of 'IO rechallenge'."@en ;
  schema:url <https://onco.cc/trials/contact-03/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04338269> ;
  onco:status "negative" ;
  onco:tag "lesson:io-rechallenge" ;
  onco:phase "3" ;
  schema:startDate "2020-07-28" ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/cabozantinib/> ;
  onco:companies <https://onco.cc/companies/exelixis/> ;
  onco:people <https://onco.cc/people/sumanta-pal/>, <https://onco.cc/people/neeraj-agarwal/> .